Welcome to our dedicated page for Haemonetics Corporation news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Corporation stock.
Haemonetics Corporation (NYSE: HAE) is a global leader in blood management solutions, dedicated to improving patient care and reducing healthcare costs. The company offers a comprehensive portfolio of integrated devices, information management systems, and consulting services that address every facet of blood and plasma management. Haemonetics operates through three key segments: Plasma, Blood Center, and Hospital.
In the Plasma segment, Haemonetics focuses on providing innovative technologies for plasma collection and processing. The company's products help ensure a steady supply of high-quality plasma for the production of biopharmaceuticals and other therapeutic applications.
Within the Blood Center segment, Haemonetics offers advanced solutions for blood component collection and processing, aiding in the optimization of blood supply chains. Despite facing high competition in this segment, the company continues to innovate and enhance its product offerings.
The Hospital segment is a significant growth area for Haemonetics, providing essential tools for surgical suites and transfusion services. The company's technologies help prevent unnecessary blood transfusions and ensure the right blood product is used at the right time, improving patient outcomes.
Recently, Haemonetics has achieved several milestones, including the acquisition of Attune Medical, the manufacturer of the FDA-cleared ensoETM® esophageal cooling device. This acquisition strengthens Haemonetics' presence in the electrophysiology market and complements its vascular closure offerings.
Haemonetics also received 510(k) clearance from the U.S. FDA for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding its capabilities to serve fully heparinized patients in critical surgical procedures.
The company's financial performance remains robust, with a strong focus on revenue growth and strategic investments. Haemonetics continues to explore new markets and develop cutting-edge technologies to stay at the forefront of the healthcare industry.
To stay updated with the latest developments and financial results, Haemonetics regularly hosts investor calls and webcasts, providing transparency and insights into its ongoing projects and future plans.
Haemonetics Corporation (NYSE: HAE) has announced the schedule for its fourth quarter and fiscal year 2023 financial results. The results will be published on May 11, 2023, at 6:00 am ET, followed by a conference call with investors and analysts at 8:00 am ET the same day. Investors can access the call via a teleconference link provided in the announcement. Additionally, a live webcast will be available on the Haemonetics investor relations website. A replay of the call will be accessible for one year after the event. Haemonetics focuses on innovative medical products aimed at improving patient care and reducing healthcare costs, particularly in blood and plasma component collection and transfusion services.
Haemonetics Corporation (NYSE: HAE) announced the release of its first Corporate Responsibility Report on April 20, 2023. The report outlines the company's progress in environmental, social, and governance (ESG) initiatives for the fiscal year 2022, concluding on April 2, 2022. Key highlights include:
- Human capital initiatives aimed at attracting a diverse workforce.
- Results from the company's first greenhouse gas emissions assessment.
- Information on corporate governance, ethics, product safety, and cybersecurity.
CEO Christopher A. Simon emphasized the importance of addressing ESG risks and maintaining stakeholder trust. The report is available on Haemonetics' website.
Vivasure Medical announced its pivotal PATCH Clinical Study for the PerQseal® Closure Device has received FDA Investigational Device Exemption (IDE) approval. The study will enroll up to 188 patients in the U.S. and Europe, aiming for FDA pre-market approval and commercial launch by year-end 2023. The company also secured a €30 million strategic investment from Haemonetics as part of its Series D financing, with an option for acquisition upon milestone completion. The global market for large hole vessel closure is valued at over $300 million, with strong growth potential, emphasizing the significance of this partnership and study.
Haemonetics Corporation (NYSE: HAE) has received 510(k) clearance from the U.S. Food and Drug Administration for its next-generation Intelligent Control software for the Cell Saver Elite+ Autotransfusion System. This upgrade includes over 50 automation enhancements aimed at improving efficiency and user experience. The Cell Saver technology allows hospitals to recover patients' blood during surgeries, helping prevent unnecessary transfusions. The software upgrade enhances versatility, offering features such as Manual Mode and optimized wash volumes according to industry standards.
Haemonetics Corporation (NYSE: HAE) has announced that President and CEO Chris Simon will engage with investors during a fireside chat at the Raymond James 44th Annual Institutional Investors Conference on March 6, 2023, at 8:40 a.m. ET. The chat will be accessible via a live webcast on Haemonetics' Investor Relations website. After the event, a replay will be available for 90 days. Haemonetics specializes in innovative medical products aimed at improving patient care and lowering healthcare costs across critical medical markets, including blood and plasma collection.
Haemonetics Corporation (NYSE: HAE) announced that its third quarter fiscal 2023 financial results are accessible on its Investor Relations website. The reporting period ended on December 31, 2022. Investors and analysts are invited to a conference call on February 7, 2023, at 8:00 a.m. ET, to discuss these results. A live webcast will also be available. Earnings release and analytical tables have been posted online for review. For further information, visit Haemonetics' website.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2023 financial results on February 7, 2023, at 6:00 AM ET. A conference call for investors and analysts will follow at 8:00 AM ET on the same day, allowing participants to discuss the results and ask questions. Registration is required to access the call, and a live webcast will also be available on the company's investor relations website. A replay of the call will be accessible for one year post the event.
Haemonetics Corporation (NYSE: HAE) announced that President and CEO Chris Simon will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2023, at 2:15 PM Pacific time. The live presentation will be available via audio webcast, accessible through Haemonetics' Investor Relations website. A replay will be available for 30 days after the event. Haemonetics focuses on innovative medical solutions aimed at improving patient care and reducing healthcare costs, specifically in blood and plasma component collection.
Haemonetics Corporation (NYSE: HAE) announced that its financial results for the second quarter of fiscal 2023, ending October 1, 2022, are now available on its Investor Relations website. A conference call and webcast will occur at 8:00 a.m. ET on November 7, 2022, to discuss these results. Interested parties can access the earnings release and supplemental information via provided links. A replay will be available for one year after the conference call. Haemonetics focuses on innovative medical products for improving patient care and reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) announced plans to release its second quarter fiscal year 2023 financial results on November 7, 2022, at 6:00 am ET. An accompanying conference call will be held at 8:00 am ET the same day for investors and analysts to discuss the results. Participants can access the call via teleconference or live webcast on Haemonetics' investor relations website. A replay of the call will be available for one year starting at 11:00 am ET on November 7, 2022.
FAQ
What is the current stock price of Haemonetics Corporation (HAE)?
What is the market cap of Haemonetics Corporation (HAE)?
What does Haemonetics Corporation specialize in?
What are the main segments of Haemonetics' business?
What recent acquisitions has Haemonetics made?
What is the TEG® 6s hemostasis analyzer system?
How does Haemonetics support its plasma segment?
What are the financial highlights of Haemonetics?
How does Haemonetics improve patient care?
What was the significance of the FDA clearance for Haemonetics?
What is Haemonetics' approach to innovation?
How can investors stay updated on Haemonetics' performance?
